1. Alternative nivolumab duration and scheduling in advanced nonsmall cell lung cancer: A real‐world evidence. Issue 5 (16th September 2020) Authors: Dudnik, Elizabeth; Moskovitz, Mor; Agbarya, Abed; Gottfried, Teodor; Shochat, Tzippy; Urban, Damien; Zer, Alona; Rotem, Ofer; Moore, Assaf; Yust, Shlomit; Peled, Nir; Wollner, Mira; Bar, Jair Journal: International journal of cancer Issue: Volume 148:Issue 5(2021) Page Start: 1183 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. BIOM-01. TYROSINE KINASE INHIBITORS AS A TREATMENT OF SYMPTOMATIC CNS METASTASES IN ONCOGENE-DRIVEN NSCLC. (9th November 2020) Authors: Benouaich-Amiel, Alexandra; Gal, Omer; Dudnik, Elizabeth; Rotem, Ofer; Finket, Inbar; Peretz, Idit; Zer, Alona; Mandel, Jacob; Siegal, Tali; Bar, Jair; Yust-Katz, Shlomit Journal: Neuro-oncology Issue: Volume 22(2020)Supplement 2 Page Start: ii1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Can Ipilimumab restore immune response in advanced NSCLC after progression on anti‐PD‐1/PD‐L1 agents?. Issue 8 (16th June 2020) Authors: Sternschuss, Michal; Peled, Nir; Allen, Aaron M.; Dudnik, Elizabeth; Rotem, Ofer; Kurman, Noga; Gal, Omer; Reches, Hiba; Zer, Alona Journal: Thoracic cancer Issue: Volume 11:Issue 8(2020) Page Start: 2331 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer. (1st January 2021) Authors: Landman, Yosef; Jacobi, Oded; Kurman, Noga; Yariv, Orly; Peretz, Idit; Rotem, Ofer; Dudnik, Elizabeth; Zer, Alona; Allen, Aaron M. Journal: Oncoimmunology Issue: Volume 10:Number 1(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC). (May 2020) Authors: Sherman, Shira; Rotem, Ofer; Shochat, Tzippy; Zer, Alona; Moore, Assaf; Dudnik, Elizabeth Journal: Lung cancer Issue: Volume 143(2020) Page Start: 40 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Lower tumor volume is associated with increased benefit from immune checkpoint inhibitors in patients with advanced non‐small‐cell lung cancer. Issue 2 (6th August 2020) Authors: Icht, Oded; Domachevsky, Liran; Groshar, David; Dudnik, Elizabeth; Rotem, Ofer; Allen, Aaron M.; Peled, Nir; Reinhorn, Daniel; Jacobi, Oded; Shochat, Tzippy; Bernstine, Hanna; Zer, Alona Journal: Asia-Pacific journal of clinical oncology Issue: Volume 17:Issue 2(2021) Page Start: e125 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study. Issue 1 (27th December 2021) Authors: Peled, Nir; Kian, Waleed; Inbar, Edna; Goldstein, Iris M; Zemel, Melanie; Rotem, Ofer; Rozenblum, Anna B; Nechushtan, Hovav; Dudnik, Elizabeth; Levin, Daniel; Zer, Alona; Keren-Rosenberg, Shoshana; Yust-Katz, Shlomit; Fuchs, Vered; Remilah, Areen A; Shelef, Ilan; Roisman, Laila C Journal: Neuro-oncology advances Issue: Volume 4:Issue 1(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data. (1st January 2021) Authors: Dudnik, Elizabeth; Moskovitz, Mor; Rottenberg, Yakir; Lobachov, Anastasiya; Mandelboim, Rinat; Shochat, Tzippy; Urban, Damien; Wollner, Mira; Nechushtan, Hovav; Rotem, Ofer; Zer, Alona; Daher, Sameh; Bar, Jair Journal: Oncoimmunology Issue: Volume 10:Number 1(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi). (October 2018) Authors: Dudnik, Elizabeth; Bshara, Elias; Grubstein, Ahuva; Fridel, Ludmila; Shochat, Tzippy; Roisman, Laila C.; Ilouze, Maya; Rozenblum, Anna Belilovski; Geva, Smadar; Zer, Alona; Rotem, Ofer; Allen, Aaron M.; Peled, Nir Journal: Lung cancer Issue: Volume 124(2018) Page Start: 117 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program. (June 2022) Authors: Illini, Oliver; Fabikan, Hannah; Swalduz, Aurélie; Vikström, Anders; Krenbek, Dagmar; Schumacher, Michael; Dudnik, Elizabeth; Studnicka, Michael; Öhman, Ronny; Wurm, Robert; Wannesson, Luciano; Peled, Nir; Kian, Waleed; Bar, Jair; Daher, Sameh; Addeo, Alfredo; Rotem, Ofer; Pall, Georg; Zer, Alona... Journal: Therapeutic advances in medical oncology Issue: Volume 14(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗